Compare LADR & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LADR | NEO |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Precision Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2014 | 1999 |
| Metric | LADR | NEO |
|---|---|---|
| Price | $10.65 | $12.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $12.75 | $11.38 |
| AVG Volume (30 Days) | 742.4K | ★ 1.7M |
| Earning Date | 02-05-2026 | 02-17-2026 |
| Dividend Yield | ★ 8.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | $233,492,000.00 | ★ $709,162,000.00 |
| Revenue This Year | N/A | $10.87 |
| Revenue Next Year | $6.81 | $9.84 |
| P/E Ratio | $17.29 | ★ N/A |
| Revenue Growth | N/A | ★ 10.10 |
| 52 Week Low | $9.68 | $4.72 |
| 52 Week High | $11.92 | $19.12 |
| Indicator | LADR | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 32.73 | 64.07 |
| Support Level | $10.92 | $11.42 |
| Resistance Level | $11.21 | $12.42 |
| Average True Range (ATR) | 0.18 | 0.44 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 1.63 | 77.68 |
Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments include loans: which derives maximum profit; securities; and real estate.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.